The prognostic value of another serum ALB-based biomarker, which is the ratio of the pre-treatment serum CRP level to serum ALB level, in HCC patients has been validated in multiple lines of studies (Table 3). This evidence concerns the gene CRP and hepatocellular carcinoma.